Top Markets
Coin of the day
CARGO Therapeutics, Inc. Common Stock CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock

CRGX
株式のランク #18091
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company... CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
株価
$4.47
最終同期: 2025-08-20
時価総額
$213.06M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 CARGO Therapeutics, Inc. Common Stock (CRGX)

カテゴリー

CARGO Therapeutics, Inc. Common Stock(CRGX)の収益
Sep 2026 時点の収益 TTM: 0
CARGO Therapeutics, Inc. Common Stock の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
CARGO Therapeutics, Inc. Common Stock の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH